健康元(600380.SH):注射用美羅培南通過仿製藥一致性評價
格隆匯10月23日丨健康元(600380.SH)公佈,近日,公司全資子公司深圳市海濱製藥有限公司(以下簡稱:深圳海濱)收到國家藥監局核准簽發的《藥品補充申請批准通知書》,深圳海濱生產的注射用美羅培南通過仿製藥質量和療效一致性評價。
本品適用於成人和兒童由單一或多種對美羅培南敏感的細菌引起的感染:肺炎(包括院內獲得性肺炎)、尿路感染、婦科感染(如子宮內膜炎和盆腔炎)、皮膚軟組織感染、腦膜炎、敗血症。經驗性治療,對成人粒細胞減少症伴發熱患者,可單獨應用本品或聯合抗病毒藥或抗真菌藥使用。本品單用或與其它抗微生物製劑聯合使用可用於治療多重感染。對於中性粒細胞減少或原發性、繼發性免疫缺陷的嬰兒患者,目前尚無本品的使用經驗。
截至本公告披露日,注射用美羅培南一致性評價已累計投入的直接研發費用約為人民幣1521.05萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.